
Restoration of independent gait is one of the primary goals of rehabilitation care in patients after stroke and significantly influences their functional autonomy and quality of life. Gait impairments result from a complex interaction between structural damage to the central nervous system (CNS), disturbances in body functions, activity limitations, and the influence of environmental factors. This narrative review summarizes current approaches to the assessment and prediction of independent gait recovery within the framework of the International Classification of Functioning, Disability and Health (ICF). Clinical tests such as the Functional Ambulation Categories (FAC), the Fugl-Meyer Assessment for the Lower Extremity (FMA-LE) for sensorimotor examination of the paretic lower limb, the 10-Meter Walk Test (10MWT) for gait speed, the 6-Minute Walk Test (6MWT) for gait endurance, and the Trunk Control Test (TCT) for trunk function cover key ICF domains. These valid and reliable tools for evaluating gait also demonstrate substantial predictive value. According to internationally recognized consensus recommendations, a comprehensive assessment should additionally include tests evaluating stability and reactive postural control in standing and during gait, including the Mini-BESTest and the Dynamic Gait Index (DGI), when feasible. This standardized set of measures enables consistent evaluation of functional status in poststroke patients and supports its broader implementation in both clinical practice and research. Furthermore, structured prediction models that allow early patient stratification and improve the accuracy of estimating the likelihood of achieving functionally independent locomotion are increasingly used. The integration of clinical, imaging, and functional indicators within the ICFframework contributes to more precise neurological prognostication and supports individualized rehabilitation planning.
AIM OF THE STUDY: To characterize the clinical phenotype of adults with clinically diagnosed and genetically confirmed Dravet syndrome (DS), with particular emphasis on seizure evolution, cognitive and motor impairment, and diagnostic delay. CLINICAL RATIONALE FOR THE STUDY: An increasing number of individuals with DS survive into adulthood and require long-term neurological care. However, the adult phenotype differs from the classical childhood presentation and remains underrecognized in adult neurological practice. Recognition of an age-evolving seizure phenotype, together with intellectual disability, gait and postural abnormalities, and extrapyramidal features, may provide important diagnostic clues and prompt molecular testing in previously undiagnosed adults. MATERIAL AND METHODS: We conducted a multicenter retrospective case series of nine adults (six females and three males) fulfilling clinical diagnostic criteria for DS and carrying a pathogenic or likely pathogenic SCN1A variant. Clinical data were obtained from medical records, neurological examinations, seizure diaries, and psychological assessments performed as part of routine care. Seizure history and evolution, status epilepticus, cognitive and communication impairment, motor phenotype, and treatment history were analyzed. RESULTS: The mean age at evaluation was 27.8 years (range 21-37 years). Seizure onset occurred at a mean age of 6 months, whereas the mean age at molecular diagnosis was 13.2 years, corresponding to a mean diagnostic delay of 12.7 years. Febrile seizures occurred in eight of nine patients and persisted beyond the age of 18 years in three. Generalized tonic-clonic seizures persisted into adulthood in all patients, whereas status epilepticus occurred after the age of 18 years in only one. Intellectual disability was present in all patients and was severe or profound in six; communication impairment was observed in eight. Motor abnormalities were prominent, including gait impairment (9/9), ataxia (8/9), postural abnormalities (8/9), bradykinesia (5/9), hypomimia (5/9), and parkinsonian features (3/9). All patients had been exposed to sodium channel-blocking antiseizure medications before molecular diagnosis, with seizure worsening documented in eight of nine patients. CONCLUSIONS AND CLINICAL IMPLICATIONS: The adult phenotype of DS combines persistent drug-resistant epilepsy with intellectual and communication impairment and prominent motor dysfunction. Although generalized tonic-clonic seizures may persist, other features of the epileptic phenotype, particularly status epilepticus, become less prominent with age. Gait, postural, cerebellar, and extrapyramidal abnormalities may provide important diagnostic clues in adults with infantile-onset epilepsy and intellectual disability. Recognition of this age-evolving phenotype may facilitate molecular diagnosis and support syndrome-specific management in adult neurological practice.
INTRODUCTION: The use of tofersen, an antisense oligonucleotide against SOD1, has been recommended for the treatment of SOD1-ALS by current European guidelines. Before full approval by national health funding agencies, patients received tofersen through the Early Access Program (EAP) and/or as rescue therapy. AIM OF THE STUDY: The aim of the study was to prospectively analyze clinical outcomes and neurofilament light chain (NfL) concentration in patients participating in the EAP in Poland between October 2023 and October 2025. MATERIAL AND METHODS: Twenty patients with SOD1-ALS (11 with familial and 9 with sporadic ALS; male:female ratio, 2.2:1) were enrolled in the EAP. They carried 11 SOD1 pathological variants, the most frequent being L145S and K4E. As 1 patient withdrew after the first dose of treatment, data were collected from 19 individuals. The median age at disease onset was 49 years (33-69 years). Disease duration before treatment was 39 months (8-110 months), and the median age at initiation of tofersen treatment was 51 years (39-74 years). The analysis included demographic and genetic data, ALS functional rating scale-revised (ALSFRS- -R), ALS progression rate, forced vital capacity (FVC), adverse events, and NfL concentration in cerebrospinal fluid. RESULTS: The median duration of tofersen treatment was 16 months (7-24 months). ALSFRS-R stabilized or increased in 68% of cases. Median delta ALSFRS-R during the treatment period was 0/month. The overall median progression rate decreased significantly from 0.218/month before treatment to 0.145/month at the last assessment (p < 0.0001). The decrease was observed in all patients, including fast-progressing individuals with continuous functional decline, as well as those with the most benign disease course. Two patients developed respiratory insufficiency, while FVC did not deteriorate in the remaining subjects. NfL concentration decreased in all analyzed patients, with significant reductions after 9 and 14 months. Serious treatment-related adverse events (SAEs) occurred in 3 patients and resolved without clinical consequences in 2 individuals. Two patients died due to disease progression and/or exacerbation of a preexisting condition/SAE. CONCLUSIONS: The long-term follow-up data support the clinical efficacy and acceptable safety profile of tofersen treatment and demonstrate a biomarker response reflecting reduced axonal injury in both slow- and fast-progressing SOD1-ALS.